Genital ProlapseREPAIRNCT06296316
Real-Life Use of Transabdominal Restorelle® Meshes in Apical Prolapse Repair
An observational study of Genital Prolapse, run by Coloplast A/S at 6 sites in France.
Trial summary
The purpose of this study is to prospectively follow patients after a sacrocolpopexy with Restorelle® mesh for apical prolapse repair as part of routine care. It will help to describe the safety profile and to confirm the clinical benefits of Restorelle mesh for at least 5 to 8 years post-surgery. Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- Genital Prolapse
- What is being tested?
- Restorelle Polypropylene Mesh
- Type of treatment
- Medical device
- How many people
- 39 participants
- Where
- 6 sitesFrance
- Study dates
- 21 Nov 2023to 6 Nov 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Study population: Adult female patients presenting with apical pelvic organ prolapse which is clinically indicated for a surgical treatment with Restorelle mesh
Who may be able to join
- Female patient of at least 18 years old
- Patient presenting apical pelvic organ prolapse and being eligible to surgical treatment
- Surgeon having decided to treat the patient with a Restorelle mesh as per its CE mark indication and IFU, before patient inclusion
- Patient having received appropriate information and counselling before mesh implantation
- Patient has been provided written informed consent
Who cannot join
- Patient currently pregnant or breastfeeding
- Patient being deprived of liberty by a judicial or administrative decision, or who is under a measure of legal protection
Trial locations and contacts
6 sites in 1 country.
6 sites in 1 country
France6 sites
Polyclinique de la Baie
Avranches, Choisir Une Région, 50300
CHU Pellegrin
Bordeaux, 33076
CH La Rochelle
La Rochelle, 17019
Clinique Bon Secours
Le Puy-en-Velay, 43000
Institut Mutualiste Montsouris
Paris, 75014
CH de Saintonge
Saintes, 17108
About this study
Official title: Real-Life Use of Transabdominal Restorelle® Meshes in Apical Prolapse Repair: an Observational Post-Market Clinical Study
The purpose of this study is to prospectively follow patients after a sacrocolpopexy with Restorelle® mesh for apical prolapse repair as part of routine care. It will help to describe the safety profile and to confirm the clinical benefits of Restorelle mesh for at least 5 to 8 years post-surgery.
Read the detailed description
This study is a non-interventional, multicenter and post market clinical follow-up in adult women with apical prolapse under normal conditions of use (after a sacrocolpopexy with Restorelle mesh for apical prolapse repair as part of routine care). The patient will be followed for 1 year (or less) by the investigator as per local usual practice. At the same time, the patient will be followed via PRO (Patient Reported Outcomes) over a period of 5 to 8 years.
- Conditions
- Genital Prolapse
- Being tested
- Restorelle Polypropylene Mesh
- Keywords
- Apical prolapse, Transabdominal mesh, Pelvic organ prolapse, Sacrocolpopexy, Sacrocervicopexy, Sacrohysteropexy
- Medical subject headings
- Pelvic Organ Prolapse
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Restorelle Polypropylene MeshDevice
The Coloplast Restorelle® Polypropylene Mesh is a Class III, implantable, permanent, non-absorbable, single use device indicated to restore female pelvic floor anatomy by providing anatomical support and suspension as a bridging material to support deficient fascia that resulted in descent of the female pelvic organs (pelvic organ prolapse).
Restorelle mesh is a synthetic, macroporous mesh constructed of medical grade knitted, monofilament polypropylene.
What is being measured
The primary outcome is the main question the study is designed to answer.
The incidence rate of a surgical reintervention related to Restorelle mesh use over at least the 5 first years of post-index procedure follow-up
Measured: up to 5 years
Secondary outcomes (24)
Incidence rate of surgical reintervention related to Restorelle mesh use in patients
Measured: through study completion, at least 5 and up to 8 years
Number of patients who have only had surgical reintervention not related to Restorelle mesh use
Measured: through study completion, at least 5 and up to 8 years
Percentage of patients who have only had surgical reintervention not related to Restorelle mesh use
Measured: through study completion, at least 5 and up to 8 years
Number of patients who have had more than 1 surgical reintervention (unrelated to mesh use)
Measured: 5 years ; up to 8-year after index procedure
Percentage of patients who have had more than 1 surgical reintervention (unrelated to mesh use)
Measured: 5 years ; up to 8-year after index procedure
Description of patients who have had more than 1 surgical reintervention (unrelated to mesh use)
Measured: 5 years ; up to 8-year after index procedure
Patient impression of improvement of surgical reintervention assessed by the PGI-I-Reintervention
Patient Global Impression of Improvement (PGI-I) is a 7-point scale that provides a single global measure of condition improvement from 'very much better' to 'very much worse' after treatment. The surgery is defined as successful if the patient felt "very much better" or "much better". In case of reintervention, the patient will complete a PGI-I-Reintervention (same questionnaire as PGI-I) at 6 months after surgical reintervention.
Measured: 6 months after surgical reintervention
Number of Adverse Device Effect
Measured: through study completion, at least 5 and up to 8 years
Percentage of Adverse Device Effect
Measured: through study completion, at least 5 and up to 8 years
Number of Restorelle mesh Device Deficiencies
Measured: through study completion, at least 5 and up to 8 years
Percentage of Restorelle mesh Device Deficiencies
Measured: through study completion, at least 5 and up to 8 years
Description of Restorelle mesh Device Deficiencies
The description of identified Restorelle mesh Device Deficiencies and categorized according to the association or not with Adverse Device Effect (ADE) or Serious ADE
Measured: through study completion, at least 5 and up to 8 years
Monitoring of postoperative pain related to Restorelle mesh use using the modified TOMUS/PREM questionnaire
Post-operative pain will be reported and evaluated by the patient using the modified TOMUS/PREM questionnaire through:
- Location and Intensity VAS
- Pain duration: acute or chronic (more than 6 months)
- Treatment: types, drug name (if medication) and duration
- Persistent pain, beyond 2 weeks, will be defined as having
- pain intensity ≥ 40 (VAS) at any of locations (lower abdomen, vagina, lower back and back of legs/buttocks) or during any activity or
- pain medication use.
Measured: through study completion, at least 5 and up to 8 years
Changes of prolapse symptoms
The changes in the Pelvic Floor Disability Index (PFDI-20 questionnaire) total score and sub scores.
Pelvic Floor Distress Inventory (PDFI-20) is comprised of 3 subscales for a total of 20 questions. Each question begins with a "yes" or "no" response. If "yes," the patient must indicate how much bowl, bladder, or pelvic symptoms have been bothering them in the past 3 months on a 4-point scale that ranges from "not at all" (0) to "quite a bit" (4). The scale scores are found individually by calculating the mean value of their corresponding questions and then multiplying by 25 to obtain a value that ranges from 0 to 100 (with higher scores indicating more distress/dysfunction). The sum of the 3 scales are added together to get the PFDI-20 summary score, which ranges from 0 to 300.
Measured: Pre-index procedure ; 2 months ; 12 months ; Every year (at least 5 and up to 8 years)
Prolapse symptoms - number
The number of patients rating "yes" at "vaginal bulge" determined by the PFDI-20/POPDI-6 and requiring additional treatment for POP since index procedure
Measured: 12 months ; 5 years
Prolapse symptoms - percentage
The percentage of patients rating "yes" at "vaginal bulge" determined by the PFDI-20/POPDI-6 and requiring additional treatment for POP since index procedure
Measured: 12 months ; 5 years
Assessment of health related quality of life using the EQ-5D-5L questionnaire
The changes in QoL total score using EQ-5D-5L and their evolution. The General Health Outcome Status questionnaire (EQ-5D-5L) consists of 2 pages: the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The descriptive system comprises 5 dimensions which are divided into 5 levels of perceived problems: from level 1 indicating no problem to level 5 indicating extreme problems. The patient indicates her health state in each of the 5 dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the 5 dimensions can be combined into a 5-digit number that describes the patient's health state. The EQ VAS records the patient's self-rated health on a vertical visual analogue scale, from 'The best health you can imagine' to 'The worst health you can imagine'. The VAS can be used as a quantitative measure of health outcome that reflect the patient's own judgment.
Measured: Pre-index procedure ; 2 months ; 12 months ; Every year (at least 5 and up to 8 years)
Assessment of health related quality of life using the PFIQ-7 questionnaire
The changes in QoL total score using the Pelvic Floor Impact Questionnaire (PFIQ-7) and their evolution.
Pelvic Floor Impact Questionnaire (PFIQ-7) consists of 7 questions. The responses for each question range from "not at all" (0) to "quite a bit" (3). To get scale scores, the mean of each of the 3 scales is individually calculated, which ranges from 0-3, this number is then multiplied by 100 and then divided by 3. The scale scores are then added together to get the total PFIQ-7 score, which ranges from 0-300. A lower score means there is a lesser effect on quality of life.
Measured: Pre-index procedure ; 2 months ; 12 months ; Every year (at least 5 and up to 8 years)
Assessment of the sexual functioning by the PISQ-IR questionnaire
Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire, IUGA revised (PISQ-IR): is composed of 20 items including the scales for arousal \& orgasm, partner related, condition specific, global quality, condition impact and desire. The number of cases for each scale that can be scored. The mean and standard deviation are provided for each scale.
Measured: Pre-index procedure ; 2 months ; 12 months ; Every year (at least 5 and up to 8 years)
Assessment of the sexual functioning by the changes in dyspareunia status of patients who are sexually active.
Measured: Pre-index procedure ; 12 months
Number of patients defining success via patient global impression of improvement (PGI-I) scale
Patient Global Impression of Improvement (PGI-I) is a 7-point scale that provides a single global measure of condition improvement from 'very much better' to 'very much worse' after treatment. The surgery is defined as successful if the patient felt "very much better" or "much better".
Measured: 2 months ; 12 months ; Every year (at least 5 and up to 8 years)
Percentage of patients defining success via patient global impression of improvement (PGI-I) scale
Patient Global Impression of Improvement (PGI-I) is a 7-point scale that provides a single global measure of condition improvement from 'very much better' to 'very much worse' after treatment. The surgery is defined as successful if the patient felt "very much better" or "much better".
Measured: 2 months ;12 months ; Every year (at least 5 and up to 8 years)
Number of patients satisfied after the index procedure as assessed by the Surgical Satisfaction Questionnaire (SSQ-8).
Surgical Satisfaction Questionnaire (SSQ-8): is a validated questionnaire used to measure patient satisfaction following a surgery to correct prolapse and/or incontinence. Answers of the SSQ questions consisted of a 5-point scale ranging from "very satisfied" to "very unsatisfied" or from "yes" to "never". Patients' satisfaction is defined if answers correspond with "very satisfied" and "satisfied" or "yes" and "may be".
Measured: 2 months ; 12 months ; Every year (at least 5 and up to 8 years)
Percentage of patients satisfied after the index procedure as assessed by the Surgical Satisfaction Questionnaire (SSQ-8)
Surgical Satisfaction Questionnaire (SSQ-8): is a validated questionnaire used to measure patient satisfaction following a surgery to correct prolapse and/or incontinence. Answers of the SSQ questions consisted of a 5-point scale ranging from "very satisfied" to "very unsatisfied" or from "yes" to "never". Patients' satisfaction is defined if answers correspond with "very satisfied" and "satisfied" or "yes" and "may be".
Measured: 2 months ; 12 months ; Every year (at least 5 and up to 8 years)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Mar 2024
- Study start21 Nov 2023
- Primary completion6 Nov 2024
- Study completion6 Nov 2024
Why it stopped: From June 08, 2024, the study device was no longer marketed in France. Therefore, the sponsor decided to terminate the study prematurely.
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Genital ProlapseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 39 participants (actual)
Sponsor and investigators
- Lead sponsor
- Coloplast A/S
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- International Clinical Trials Association
- Responsible party
- Sponsor
- Investigators
- Philippe Ferry, Dr, Principal investigator, CH La Rochelle, France
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06296316
- Sponsor's protocol ID
- IU022
- Acronym
- REPAIR
- Status last verified
- Jan 2026
- First submitted
- 24 Nov 2023
- Last updated
- 28 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: There is not a plan to make IPD available
Study at a glance
From the registry record, last updated by the sponsor on 28 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Real-Life Use of Transabdominal Restorelle® Meshes in Apical Prolapse Repair: an Observational Post-Market Clinical Study
- ClinicalTrials.gov ID
- NCT06296316
- Acronym / sponsor ID
- REPAIR / IU022
- Conditions
- Genital Prolapse
- Keywords
- Apical prolapse, Transabdominal mesh, Pelvic organ prolapse, Sacrocolpopexy, Sacrocervicopexy, Sacrohysteropexy
- Study type
- Observational
- Recruitment status
- TerminatedReason stopped: From June 08, 2024, the study device was no longer marketed in France. Therefore, the sponsor decided to terminate the study prematurely.
- Enrolment
- 39 participants (actual)
- Lead sponsor
- Coloplast A/SIndustry (pharma, biotech, devices)
- Collaborators
- International Clinical Trials Association
- Study start
- 21 Nov 2023 (actual)
- Primary completion
- 6 Nov 2024 (actual)
- Study completion
- 6 Nov 2024 (actual)
- First posted
- 6 Mar 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to prospectively follow patients after a sacrocolpopexy with Restorelle® mesh for apical prolapse repair as part of routine care. It will help to describe the safety profile and to confirm the clinical benefits of Restorelle mesh for at least 5 to 8 years post-surgery.
Detailed description
This study is a non-interventional, multicenter and post market clinical follow-up in adult women with apical prolapse under normal conditions of use (after a sacrocolpopexy with Restorelle mesh for apical prolapse repair as part of routine care). The patient will be followed for 1 year (or less) by the investigator as per local usual practice. At the same time, the patient will be followed via PRO (Patient Reported Outcomes) over a period of 5 to 8 years.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adult female patients presenting with apical pelvic organ prolapse which is clinically indicated for a surgical treatment with Restorelle mesh
Key inclusion criteria (5 listed)
- Female patient of at least 18 years old
- Patient presenting apical pelvic organ prolapse and being eligible to surgical treatment
- Surgeon having decided to treat the patient with a Restorelle mesh as per its CE mark indication and IFU, before patient inclusion
- Patient having received appropriate information and counselling before mesh implantation
- Patient has been provided written informed consent
Key exclusion criteria (2 listed)
- Patient currently pregnant or breastfeeding
- Patient being deprived of liberty by a judicial or administrative decision, or who is under a measure of legal protection
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Restorelle Polypropylene MeshThe Coloplast Restorelle® Polypropylene Mesh is a Class III, implantable, permanent, non-absorbable, single use device indicated to restore female pelvic floor anatomy by providing anatomical support and suspension as a bridging material to support deficient fascia that resulted in descent of the female pelvic organs (pelvic organ prolapse). Restorelle mesh is a synthetic, macroporous mesh constructed of medical grade knitted, monofilament polypropylene. | Device | – |
Primary outcome
The incidence rate of a surgical reintervention related to Restorelle mesh use over at least the 5 first years of post-index procedure follow-up
Time frame: up to 5 years
24 secondary outcomes
Incidence rate of surgical reintervention related to Restorelle mesh use in patients
Time frame: through study completion, at least 5 and up to 8 years
Number of patients who have only had surgical reintervention not related to Restorelle mesh use
Time frame: through study completion, at least 5 and up to 8 years
Percentage of patients who have only had surgical reintervention not related to Restorelle mesh use
Time frame: through study completion, at least 5 and up to 8 years
Number of patients who have had more than 1 surgical reintervention (unrelated to mesh use)
Time frame: 5 years ; up to 8-year after index procedure
Percentage of patients who have had more than 1 surgical reintervention (unrelated to mesh use)
Time frame: 5 years ; up to 8-year after index procedure
Description of patients who have had more than 1 surgical reintervention (unrelated to mesh use)
Time frame: 5 years ; up to 8-year after index procedure
Patient impression of improvement of surgical reintervention assessed by the PGI-I-Reintervention
Time frame: 6 months after surgical reintervention
Number of Adverse Device Effect
Time frame: through study completion, at least 5 and up to 8 years
Percentage of Adverse Device Effect
Time frame: through study completion, at least 5 and up to 8 years
Number of Restorelle mesh Device Deficiencies
Time frame: through study completion, at least 5 and up to 8 years
Percentage of Restorelle mesh Device Deficiencies
Time frame: through study completion, at least 5 and up to 8 years
Description of Restorelle mesh Device Deficiencies
Time frame: through study completion, at least 5 and up to 8 years
Monitoring of postoperative pain related to Restorelle mesh use using the modified TOMUS/PREM questionnaire
Time frame: through study completion, at least 5 and up to 8 years
Changes of prolapse symptoms
Time frame: Pre-index procedure ; 2 months ; 12 months ; Every year (at least 5 and up to 8 years)
Prolapse symptoms - number
Time frame: 12 months ; 5 years
Prolapse symptoms - percentage
Time frame: 12 months ; 5 years
Assessment of health related quality of life using the EQ-5D-5L questionnaire
Time frame: Pre-index procedure ; 2 months ; 12 months ; Every year (at least 5 and up to 8 years)
Assessment of health related quality of life using the PFIQ-7 questionnaire
Time frame: Pre-index procedure ; 2 months ; 12 months ; Every year (at least 5 and up to 8 years)
Assessment of the sexual functioning by the PISQ-IR questionnaire
Time frame: Pre-index procedure ; 2 months ; 12 months ; Every year (at least 5 and up to 8 years)
Assessment of the sexual functioning by the changes in dyspareunia status of patients who are sexually active.
Time frame: Pre-index procedure ; 12 months
Number of patients defining success via patient global impression of improvement (PGI-I) scale
Time frame: 2 months ; 12 months ; Every year (at least 5 and up to 8 years)
Percentage of patients defining success via patient global impression of improvement (PGI-I) scale
Time frame: 2 months ;12 months ; Every year (at least 5 and up to 8 years)
Number of patients satisfied after the index procedure as assessed by the Surgical Satisfaction Questionnaire (SSQ-8).
Time frame: 2 months ; 12 months ; Every year (at least 5 and up to 8 years)
Percentage of patients satisfied after the index procedure as assessed by the Surgical Satisfaction Questionnaire (SSQ-8)
Time frame: 2 months ; 12 months ; Every year (at least 5 and up to 8 years)
Results and safety
The study was stopped early (reason given: From June 08, 2024, the study device was no longer marketed in France. Therefore, the sponsor decided to terminate the study prematurely.). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Jan 2026.
- Individual participant dataSharing planned: No. There is not a plan to make IPD available
Related trials for Genital Prolapse
Active, not recruitingObservational study
i-Stitch for Bilateral Sacrospinous Ligament Fixation (SSLF)
Pelvic Organ Prolapse, Genital Prolapse
Recruiting
Pelvic Floor Muscle Training During Pregnancy
Urinary Incontinence, Anal Incontinence
Not yet recruiting
Perineal Protection Device for Reducing Perineal Trauma During Vaginal Delivery in First-time Mothers: a Multicenter Randomized Controlled Trial
Pelvic Floor Dysfunction, Perineal Laceration
Active, not recruiting
Patient-Centered Outcomes in the Surgical Treatment of Uterovaginal Prolapse
Uterine Prolapse
Recruiting
Functional Links Between the Temporomandibular Joint and the Pelvis in Gynecology
Prolapse; Female, Endometriosis-related Pain
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Philippe Ferry, Dr principal investigator
CH La Rochelle, France
6 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Genital Prolapse, run by Coloplast A/S at 6 sites in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 28 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 6 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was stopped early (reason given: From June 08, 2024, the study device was no longer marketed in France. Therefore, the sponsor decided to terminate the study prematurely.). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The incidence rate of a surgical reintervention related to Restorelle mesh use over at least the 5 first years of post-index procedure follow-up (time frame: up to 5 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Jan 2026.